KUALA LUMPUR, July 29 -- Allurion Technologies has entered Asia with the launch of the Elipse® Gastric Balloon Weight Loss Program in Hong Kong, Malaysia and Singapore.
The company’s entry into Asia could impact the lives of over one billion people who are overweight or obese that historically has had limited access to non-invasive weight loss treatments. “The arrival of the Elipse Balloon in Gleneagles Hospital Penang was a historical moment for all of us involved,” said Dr Kirubakaran Malapan of Gleneagles Hospital Penang. “I am very confident that this will be an appealing treatment option in our fight against obesity.” Allurion has already treated over 25,000 individuals in over 30 countries with its 360-degree Allurion weight loss programme. Based on a study released by the Asian Development Bank Institute, over 40 per cent of adults in Asia are overweight or obese, an increase of close to 20 per cent in just the past 20 years. According to Allurion co-founder and Chief Executive Officer, Shantanu Gaur, M.D. in a statement, obesity has been on the rise in Asia for decades, but truly frictionless treatment options have been absent and they intend to change that. In the same statement, Allurion also announced the addition of John Liljequist as Director of Asia Pacific Sales, bringing over 18 years of commercial medical device experience in the Asia Pacific region. -- BERNAMA
0 Comments
Leave a Reply. |
Archives
April 2023
Categories |